Get the app
US › Healthcare

EyePoint, Inc (EYPT)

US · Healthcare · Biotechnology

$2.99-4.78%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$507,000
Revenue YoY
-90.5%
Net profit
$-94.5M
EPS
$-1.09
EPS estimate
$-0.92
Net margin
-18,633.1%

EPS came in at -1.09 against a street estimate of -0.92 — a miss of 18.5%.

Key statistics

Market cap
$263.3M
Forward P/E
6.2
P/B
2.11
Book value
$1.96
EPS (TTM)
$-3.87
52-week high
$19.11
52-week low
$2.93
50-day MA
$5.40
200-day MA
$11.88
Beta
1.68

Analyst view

Analysts rate EyePoint, Inc a buy (7 buy, 6 hold, 0 sell out of 13) with an average price target of $25.91.

Shareholding

Insiders
3.52%
Institutions
117.62%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC9.62%
BlackRock Inc8.66%
Cormorant Asset Management, LLC8.12%
Federated Hermes Inc6.59%
Adage Capital Partners Gp LLC5.60%
Franklin Templeton Inc5.58%
COMMODORE CAPITAL LP5.34%
Jupiter Topco LLC4.37%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for EyePoint, Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.